SecBot SecBot
8-K ·Filed Jul 24, 2026

MD

Pediatrix Medical Group, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001193125-26-316225
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

This is a routine executive succession with no immediate trading signal. Monitor for any future strategic shifts under the new General Counsel, but no near-term price catalyst is expected.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
MD ▲ +4.44% at T+60d
NEUTRAL call +4.44% · α vs SPY +0.73% · entry $26.14 → $27.30
Entry = T+0 close
Jul 24, 2026
via day close
T+1d
+2.75%
call +2.75% · α +2.51%
$26.86
settled 3mo ago
T+5d
+1.42%
call +1.42% · α +0.34%
$26.51
settled 3mo ago
T+20d
+1.76%
call +1.76% · α -1.54%
$26.60
settled 2mo ago
T+60d
+4.44%
call +4.44% · α +0.73%
$27.30
settled 8d ago

Price Chart

Loading chart...

Executive Summary

Pediatrix Medical Group filed an 8-K announcing the departure of EVP, General Counsel, Chief Administrative Officer and Secretary Mary Ann E. Moore, effective October 31, 2026, under a separation agreement. The company simultaneously appointed David Haddock as the new EVP, General Counsel and Secretary. This is a routine executive transition with no material financial impact disclosed.

Key Facts

  • Mary Ann E. Moore will transition from her role as EVP, General Counsel, Chief Administrative Officer and Secretary, effective October 31, 2026.
  • Moore entered into a Separation Agreement with a PMG subsidiary on July 21, 2026, and will serve in an advisory role until her departure.
  • The transition is classified as a termination without cause, and Moore will receive the benefits specified in her employment agreement.
  • David Haddock has been appointed as the new Executive Vice President, General Counsel and Secretary.

Financial Impact

No financial impact disclosed; separation benefits are standard contractual obligations.

Risk Factors

  • Potential disruption from loss of institutional knowledge during the transition period.
  • No disclosed financial terms of the separation agreement, leaving open the possibility of material severance costs.

Market Snapshot

Exchange
NYSE
Sector
Services-Hospitals
Analyst Consensus
60% bullish (15 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-316225
Document: 0001193125-26-316225-index-headers.html0001193125-26-316225
Document: 0001193125-26-316225-index.html0001193125-26-316225
Document: 0001193125-26-316225.txt0001193125-26-316225
5 reports for MD
Performance horizon
Filters
Rows
Reports for MD — sortable, filterable
TypeNow
Aug 4, 2026
12w ago
8-K
NEUTRAL ★ 5/10
$24.71 $26.47▲ +7.12%▲ +8.36%$28.92 (+17.04%)
Jul 24, 2026
13w ago
8-K
NEUTRAL ★ 2/10
$26.14 $26.60▲ +1.76%▼ −1.54%$28.92 (+10.64%)
Jul 15, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$25.88 $26.50▲ +2.40%▲ +0.05%$28.92 (+11.75%)
Apr 17, 2026
27w ago
DEFA14A
NEUTRAL ★ 3/10
$23.19 $22.64▼ −2.37%▼ −6.57%$28.92 (+24.71%)
Mar 27, 2026
30w ago
DEFA14A
NEUTRAL ★ 2/10
$20.50 $23.39▲ +14.10%▲ +1.36%$28.92 (+41.07%)
Showing 5 of 5

US Market Status

Market Open — Closes in 4h 28m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 24, 2026